SecSonar.com

Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Tango Therapeutics, Inc. (TNGX) is a Biotechnology company based in US with a market capitalization of $2.4B. Revenue grew 48.3% year-over-year and free cash flow was negative at -$139.9M. This page tracks TNGX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 155 employees · IPO Sep 3, 2020

Valuation

Valuation & price

$20.56 · as of May 17, 2026 · -37.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.04

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$32.90$19.16$5.43Jul 25Dec 25Jul 26Jul 7, 25$5.43Jul 9, 25$6.04Jul 11, 25$5.93Jul 15, 25$5.91Jul 17, 25$6.86Jul 21, 25$6.77Jul 23, 25$6.88Jul 25, 25$6.82Jul 29, 25$6.46Jul 31, 25$6.04Aug 4, 25$6.59Aug 6, 25$6.50Aug 11, 25$6.41Aug 13, 25$6.88Aug 15, 25$6.77Aug 19, 25$6.96Aug 21, 25$7.01Aug 25, 25$6.72Aug 27, 25$6.90Aug 29, 25$6.71Sep 3, 25$6.70Sep 5, 25$6.94Sep 9, 25$6.82Sep 11, 25$6.84Sep 16, 25$7.35Sep 18, 25$7.87Sep 22, 25$7.45Sep 24, 25$7.80Sep 26, 25$8.53Sep 30, 25$8.40Oct 2, 25$7.69Oct 6, 25$7.58Oct 8, 25$6.91Oct 10, 25$7.14Oct 14, 25$8.70Oct 16, 25$9.17Oct 21, 25$8.99Oct 23, 25$7.53Oct 27, 25$7.77Oct 29, 25$7.83Oct 31, 25$8.11Nov 4, 25$8.01Nov 6, 25$8.01Nov 10, 25$7.93Nov 12, 25$7.67Nov 14, 25$8.17Nov 18, 25$8.00Nov 20, 25$8.90Nov 25, 25$10.57Nov 28, 25$10.91Dec 2, 25$10.08Dec 4, 25$9.90Dec 8, 25$9.60Dec 10, 25$9.17Dec 12, 25$9.35Dec 16, 25$8.96Dec 18, 25$8.46Dec 22, 25$8.62Dec 24, 25$8.70Dec 29, 25$8.75Jan 2, 26$8.93Jan 6, 26$9.67Jan 8, 26$11.06Jan 12, 26$10.66Jan 14, 26$12.39Jan 16, 26$13.01Jan 21, 26$12.51Jan 23, 26$11.71Jan 27, 26$11.85Jan 29, 26$11.67Feb 2, 26$11.94Feb 4, 26$12.32Feb 9, 26$12.89Feb 11, 26$12.61Feb 13, 26$12.90Feb 18, 26$12.41Feb 20, 26$12.20Feb 24, 26$12.88Feb 26, 26$11.40Mar 2, 26$11.53Mar 4, 26$12.35Mar 6, 26$16.95Mar 10, 26$16.50Mar 12, 26$17.15Mar 17, 26$18.68Mar 19, 26$19.32Mar 23, 26$18.96Mar 25, 26$20.88Mar 27, 26$19.26Mar 31, 26$20.92Apr 2, 26$21.63Apr 7, 26$19.80Apr 9, 26$20.70Apr 13, 26$21.56Apr 15, 26$25.33Apr 17, 26$26.64Apr 22, 26$26.94Apr 24, 26$25.77Apr 28, 26$25.14Apr 30, 26$21.62May 4, 26$22.71May 6, 26$23.62May 8, 26$23.02May 12, 26$23.50May 14, 26$24.87May 18, 26$20.63May 20, 26$21.08May 22, 26$20.24May 28, 26$20.00Jun 1, 26$23.10Jun 3, 26$21.47Jun 5, 26$20.22Jun 9, 26$31.56Jun 11, 26$29.82Jun 15, 26$32.90Jun 17, 26$32.29Jun 22, 26$28.50Jun 24, 26$29.12Jun 26, 26$31.47Jul 2, 26$29.46
$5.4352-week range$32.90
Loading valuation history…

Fundamentals

Key fundamentals

$2.4B

Market cap

48.3%

Revenue growth (YoY)

96.3%

Gross margin

-$139.9M

Free cash flow (USD)

-$309.6M

Net debt

Net cash position

6.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$24.6MFY 2020$7.7MFY 2021$37.0MFY 2022$24.9MFY 2023$36.5MFY 2024$42.1MFY 2025$62.4M
$24.6M$62.4M

Free cash flow by year

2019 → 2025

FY 2019$-26.6MFY 2020$69.0MFY 2021$-61.4MFY 2022$-116.8MFY 2023$-119.5MFY 2024$-132.3MFY 2025$-139.9M
-$26.6M-$139.9M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202596.3%
100.0%96.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

4

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $799K · 10b5-1 PlanCrystal Adam · President, R&D · $798.9KJul 2, 2026Filing
  • 8-K eventDirector AppointmentJun 23, 2026Filing
  • 8-K eventStock OfferingJun 10, 2026Filing
  • 8-K eventClinical Data PresentationJun 8, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 4, 2026Filing
  • Insider sellInsider Sell $618K · 10b5-1 PlanCrystal Adam · President, R&D · $617.6KJun 3, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • 8-K eventSeparation AgreementMay 8, 2026Filing
  • Insider sellInsider Sell $573K · 10b5-1 PlanCrystal Adam · President, R&D · $573.1KMay 5, 2026Filing

Questions

Frequently asked questions

What is Tango Therapeutics, Inc.'s market cap?

Tango Therapeutics, Inc. (TNGX) has a market capitalization of $2.4B.

What is TNGX's P/E ratio?

A meaningful P/E ratio is not available for TNGX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is TNGX's price-to-book (P/B) ratio?

TNGX trades at 7.04 times book value per share.

Are insiders buying TNGX stock?

SEC Form 4 filings show no open-market insider buys at Tango Therapeutics, Inc. in the last 90 days (4 sells).

Same arena

Related companies in Biotechnology

ADPT

Adaptive Biotechnologies Corporation

$2.5B

ANAB

AnaptysBio, Inc.

$2.4B

RARE

Ultragenyx Pharmaceutical Inc.

$2.4B

RCUS

Arcus Biosciences, Inc.

$2.5B

TARS

Tarsus Pharmaceuticals, Inc.

$2.6B

IDYA

IDEAYA Biosciences, Inc.

$2.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.